Dr Alexander Lewis
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology
16 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia
DOI: 10.1016/j.cell.2025.10.0282022
Journal article
The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism
DOI: 10.1038/s41598-021-04009-w2022
Journal article
Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells
DOI: 10.1016/j.celrep.2022.1111822022
Journal article
Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia
DOI: 10.15252/emmm.2021152032022
Journal article
Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia
DOI: 10.1182/blood.20210132772022
Journal article
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
DOI: 10.1038/s41375-022-01571-82021
Journal article
Non-genetic heterogeneity, altered cell fate and differentiation therapy
DOI: 10.15252/emmm.202012670
RECENT SCHOLARLY WORKS
2020
Journal article
Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models
DOI: 10.1182/BLOODADVANCES.20200015762020
Journal article
ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism
DOI: 10.1038/s41556-020-0523-y2020
Journal article
Publisher Correction: ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism (Nature Cell Biology, (2020), 22, 7, (882-895), 10.1038/s41556-020-0523-y)
DOI: 10.1038/s41556-020-0539-3